1.13
-0.05(-4.24%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.19 |
| Day High | 1.2 |
| Day Low | 1.12 |
| 52-Week High | 3.94 |
| 52-Week Low | 0.69 |
| Volume | 1.78M |
| Average Volume | 4.57M |
| Market Cap | 223.96M |
| PE | -1.33 |
| EPS | -0.85 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.7 |
| Change | -0.05 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $11.69 as of July 15, 2025 at a share price of $1.13. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $23.06 as of July 15, 2025 at a share price of $1.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord
Esperion Appoints Craig Thompson to Board of Directors
GlobeNewswire Inc.
Jul 01, 2025 12:06 PM GMT
Brings More Than Twenty Years of Biopharmaceutical Leadership ExperienceANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Lim